Centro Médico San Roque S.R.L. - Tucumán

Centro Médico San Roque S.R.L. - Tucumán
Balcarce 579, Tucumán
Select an option
Our team
Medical staff
Juan Jose Zarba
Open studies
Breast Cancer
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and CompanySee more
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy - CAMBRIA-1 - AstraZenecaSee more
Skin cancer
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma - Regeneron PharmaceuticalsSee more
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery - Regeneron PharmaceuticalsSee more
Advanced tumors
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) - MK-3475-587 - Merck Sharp & Dohme Corp.See more
Kidney cancer
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC - SAMETA - AstraZenecaSee more
Solid tumors
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) - MK-3475-587 - Merck Sharp & Dohme Corp.See more
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy